GHRP-6

researchGH Axis

Evidence grade

DResearch/compounded/adjunct (no established FDA indication)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeGH axis

MechanismGrowth hormone secretagogue; may increase appetite

EffectsSignals the GH axis; can affect body composition, fluid retention, and glucose

DosingNo human dose established.

Bottom linePopular in research/compounding; human safety/benefit not well-established.

Protocols · as published2 sourced

Clinical trialMechanistic study in healthy men (Pandya, JCEM 1998)

RouteIntravenous bolus

FrequencySingle bolus

Starting1 mcg/kg IV

EscalationNone

TargetMechanistic study, not a regimen

SourcePubMed 9543138 ↗

Community protocol — not clinically establishedCommunity guide

RouteSubcutaneous

Frequency3x daily, at least 4 h apart

Starting100 mcg per injection, weeks 1-2

Escalation200 mcg weeks 3-4

Target300 mcg per injection, weeks 5-12, 3x daily ("the saturation point")

Cycle"Several weeks to a few months"; planning examples 4-12 weeks

Sourcepeptidedosingprotocols.com ↗

Batches on filenone

No tested batches on file.

Read with10

IGF-1 LR3 Octreotide Lanreotide Semaglutide Tirzepatide Liraglutide Exenatide Dulaglutide Pramlintide Cagrilintide

Cautions & interactions

Not FDA-approved; endocrine risks

Can raise glucose; monitor if on diabetes meds; fluid retention may affect BP/CHF; avoid with active malignancy (per clinical guidance).

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.